Urinary factors for calcium urolithiasis and their correction


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Drugs for preventing stone formation can be selected based on the average regional indicators, which have features depending on the region of the world. Aim. To investigate the features of urinary factors for lithogenesis (UFL) of calcium urolithiasis in Tashkent and evaluate the variants of their pharmacological correction. Materials and methods. The study analyzed data from 779 patients with calcium urolithiasis. Ninety-nine patients with uncomplicated calcium urolithiasis received non-selective preventive pharmacotherapy. Of them, patients of group 1 (n=21), 2 (n=56) and 3 (n=22) received alkaline citrate (AC) for 1 month, phytotherapy (PT) for 2 months, and combined therapy (AC + PT) for 1 month, respectively. Statistics of UFL in 779 patients with calcium urolithiasis were calculated, and the results of non-selective prophylaxis in 99 patients with uncomplicated calcium urolithiasis were analyzed. Results. The most common UFLs were hypocitraturia (96.7%), decreased diuresis (96.3%), and hyperoxaluria (92.94%). In the patients of group 1, the treatment resulted in an increase in citrate by 54.14% and urine pH by 18.63%; diuresis did not change, and CaOx decreased by 50.63%. In group 2, there was an increase in citrate by 3.88% (on average for 2 months), urine pH by 10.82%, and diuresis by 32.17%; CaOx decreased by 32.59%. In group 3, citrate increased by 71.52%, urine pH by 18.07%, and diuresis by 34.71%; CaOx decreased by 69.15%. Correction of citraturia was effective in patients with initial hypocitraturia: in 80.95%, 78.6%, and 86.4% in groups 1-3, respectively. Conclusion. The findings confirm the potential of empirical therapy based on the average statistical indicators of the region. The combination of AC (Litren) and PT (Canephron N) proved to be most effective: CaOx decreased to a low level, it was possible to compensate for the undesirable effects of prolonged intake of the synthetic drug (AC). Nevertheless, we believe that long-term controlled studies are needed to confirm the validity of this approach, and the results of this study should be regarded as promising.

Texto integral

Acesso é fechado

Sobre autores

A. Gaibullaev

Institute of Postgraduate Medical Education

Email: gaybullaiev52@mail.ru
Dr.Med.Sci., Professor, Head of the Department of Urology

S. Kariev

Tashkent Institute of Postgraduate Medical Education

Email: saidakhror@mail.ru
Associate Professor at the Department of Urology and Nephrology

Bibliografia

  1. Talati J.J., Tiselius H.G., Albala D.M., YE Z. Urolithiasis. Basic Science and Clinical Practice. ISBN: 978-14471-4383 (Print), Springer London, 2012.
  2. Pietrow P.K., Karellas M.E. Medical Management of Common Urinary CaicuIi. Am Fam Physician. 2006;74(1):86-100.
  3. Uribarri J., Oh M.S., Carroll H.J. The first kidney stone. Ann Intern Med. 1989;111:1006-1009.
  4. Goldfarb D.S., Arowojolu O. Metabolic Evaluation of First-time and Recurrent Stone Formers. Uroi Ciin North Am. 2013;40(1):13-20.
  5. Урология / Под ред. Н. А. Лопаткина. М.: ГЭОТАР-Медиа, 2010
  6. Basavaraj D.R., Biyani Ch.Sh., Browning A.J., Cartledge J.J. The Roie of Urinary Kidney Stone Inhibitors and Promoters in the Pathogenesis of Calcium Containing Renai Stones. EAU - EBU Update series. 2007;5:126-136.
  7. Alan J. Wei«, Louis R. Kavoussi, Alan W. Partin and Craig A. Peters edit Campbeii-Waish Uroiogy, 11th Edition, Voi.2. Urinary Lithiasis and Endouroiogy.
  8. Кариев С.С., Гайбуллаев О.А. Мочекаменная болезнь: с чего следует начинать профилактику повторного камнеобразования? Здоровье Узбекистана. 2017;5(16):70-73
  9. Gaybullaev A.A., Kariev S.S., Tursunov B.Sh. Metaboiic evaiuation the patients with the ICUL. Uroi Res. 2008;36:157.
  10. Клепиков Ф.А., Томах Ю.Ф., Антонян И.М. Кристаллурия. Урология и нефрол. 1991;6:22-25
  11. Tiselius H.G., Nogueira Ferraz R.R., Heilberg I.P. An approximate estimate of the ion-activity product of caicium oxaiate in rate urine. Uroi Res. 2003;31:410-413.
  12. Hesse A., Tiselius H.-G., Siener R., Hoppe B.S., Karger AG. Basei Urinary Stones: Diagnosis, Treatment, and Prevention of recurrence., 2009 3rd Ed.
  13. Gaybullaev A.A., Kariev S.S., Mi«A.V. Metaboiic evaiuation of patients with CaOx Uroiithiasis and preuroiithiasis. Abstracts from the 10th European Symposium on Uroiithiasis. Istanbui, Turkey, June 2003;85:11-14.
  14. Акилов Ф.А., Солиев Т.Х. Отчет по клинической апробации препарата Литрен АТМ. 2015;15 с
  15. Гончарова Т.А. Энциклопедия лекарственных растений. М.: МСП, 1999;3-7
  16. Gaybullaev A.A., Kariev S.S. Effects of the herbal combination Canephron N on urinary risk factors of idiopathic calcium urolithiasis in an open study. Zeitschrift fur Phytotherapie. 2013;34:16-20.
  17. Rodgers A.L., Webber D., Ramsout R., Gohel M.D.I. Herbal preparations affect the kinetic factors of calcium oxalate crystallization in synthetic urine: implications for kidney stone therapy Urolithiasis. 2014;42(3): 221-225.
  18. Pak C.Y. Hypercalciuric calcium nephrolithiasis. In Resnick MI, Pak C.Y. (eds): Urolithiasis: A Medical and Surgical Reference. Philadelphia, W.B. Saunders. 1990;79-88.
  19. Baruch S.B., Burich R.L., Eun C.K., King V.F. Renal metabolism of citrate. Med Clin North Am. 1975;59:569-582.
  20. Down W.H., Sacharin R.M., Chasseaud L.F., Kirkpatrick D., Franklin E.R. Renal and bone uptake of tartaric acid in rats: Comparison of L+ and DL-forms. Toxicology. 1977;8:333-334.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2018

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies